189 related articles for article (PubMed ID: 28529647)
1. Redox Responsive Hyaluronic Acid Nanogels for Treating RHAMM (CD168) Over-expressive Cancer, both Primary and Metastatic Tumors.
Yang C; Li C; Zhang P; Wu W; Jiang X
Theranostics; 2017; 7(6):1719-1734. PubMed ID: 28529647
[TBL] [Abstract][Full Text] [Related]
2. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels.
Lee H; Mok H; Lee S; Oh YK; Park TG
J Control Release; 2007 Jun; 119(2):245-52. PubMed ID: 17408798
[TBL] [Abstract][Full Text] [Related]
3. Bio-derived poly(gamma-glutamic acid) nanogels as controlled anticancer drug delivery carriers.
Bae HH; Cho MY; Hong JH; Poo H; Sung MH; Lim YT
J Microbiol Biotechnol; 2012 Dec; 22(12):1782-9. PubMed ID: 23221543
[TBL] [Abstract][Full Text] [Related]
4. NIR and UV-responsive degradable hyaluronic acid nanogels for CD44-targeted and remotely triggered intracellular doxorubicin delivery.
Hang C; Zou Y; Zhong Y; Zhong Z; Meng F
Colloids Surf B Biointerfaces; 2017 Oct; 158():547-555. PubMed ID: 28743090
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors.
Wei X; Senanayake TH; Warren G; Vinogradov SV
Bioconjug Chem; 2013 Apr; 24(4):658-68. PubMed ID: 23547842
[TBL] [Abstract][Full Text] [Related]
6. Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates.
Cai S; Alhowyan AA; Yang Q; Forrest WC; Shnayder Y; Forrest ML
J Drug Target; 2014 Aug; 22(7):648-57. PubMed ID: 24892741
[TBL] [Abstract][Full Text] [Related]
7. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 2 (TLR2), transforming growth factor-β, hyaluronan (HA), and receptor for HA-mediated motility (RHAMM) are required for surfactant protein A-stimulated macrophage chemotaxis.
Foley JP; Lam D; Jiang H; Liao J; Cheong N; McDevitt TM; Zaman A; Wright JR; Savani RC
J Biol Chem; 2012 Oct; 287(44):37406-19. PubMed ID: 22948158
[TBL] [Abstract][Full Text] [Related]
9. Receptor for Hyaluronic Acid-mediated Motility (RHAMM) Is Associated With Prostate Cancer Migration and Poor Prognosis.
Minato A; Kudo Y; Noguchi H; Kohi S; Hasegawa Y; Sato N; Hirata K; Fujimoto N
Cancer Genomics Proteomics; 2023; 20(2):203-210. PubMed ID: 36870687
[TBL] [Abstract][Full Text] [Related]
10. Targeted intracellular protein delivery based on hyaluronic acid-green tea catechin nanogels.
Liang K; Ng S; Lee F; Lim J; Chung JE; Lee SS; Kurisawa M
Acta Biomater; 2016 Mar; 33():142-52. PubMed ID: 26785145
[TBL] [Abstract][Full Text] [Related]
11. The Receptor for Hyaluronan-Mediated Motility (CD168) promotes inflammation and fibrosis after acute lung injury.
Cui Z; Liao J; Cheong N; Longoria C; Cao G; DeLisser HM; Savani RC
Matrix Biol; 2019 May; 78-79():255-271. PubMed ID: 30098420
[TBL] [Abstract][Full Text] [Related]
12. Intracellularly Swollen Polypeptide Nanogel Assists Hepatoma Chemotherapy.
Shi B; Huang K; Ding J; Xu W; Yang Y; Liu H; Yan L; Chen X
Theranostics; 2017; 7(3):703-716. PubMed ID: 28255361
[TBL] [Abstract][Full Text] [Related]
13. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
[TBL] [Abstract][Full Text] [Related]
14. Receptor for hyaluronan-mediated motility (RHAMM) defines an invasive niche associated with tumor progression and predicts poor outcomes in breast cancer patients.
Tarullo SE; He Y; Daughters C; Knutson TP; Henzler CM; Price MA; Shanley R; Witschen P; Tolg C; Kaspar RE; Hallstrom C; Gittsovich L; Sulciner ML; Zhang X; Forster CL; Lange CA; Shats O; Desler M; Cowan KH; Yee D; Schwertfeger KL; Turley EA; McCarthy JB; Nelson AC
J Pathol; 2023 Jul; 260(3):289-303. PubMed ID: 37186300
[TBL] [Abstract][Full Text] [Related]
15. Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling.
Song JM; Molla K; Anandharaj A; Cornax I; O Sullivan MG; Kirtane AR; Panyam J; Kassie F
Oncotarget; 2017 Apr; 8(16):26927-26940. PubMed ID: 28460475
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronic acid, CD44 and RHAMM regulate myoblast behavior during embryogenesis.
Leng Y; Abdullah A; Wendt MK; Calve S
Matrix Biol; 2019 May; 78-79():236-254. PubMed ID: 30130585
[TBL] [Abstract][Full Text] [Related]
17. Folate conjugated hyaluronic acid coated alginate nanogels encapsulated oxaliplatin enhance antitumor and apoptosis efficacy on colorectal cancer cells (HT29 cell line).
Shad PM; Karizi SZ; Javan RS; Mirzaie A; Noorbazargan H; Akbarzadeh I; Rezaie H
Toxicol In Vitro; 2020 Jun; 65():104756. PubMed ID: 31884114
[TBL] [Abstract][Full Text] [Related]
18. The impact of the receptor of hyaluronan-mediated motility (RHAMM) on human urothelial transitional cell cancer of the bladder.
Niedworok C; Kretschmer I; Röck K; Vom Dorp F; Szarvas T; Heß J; Freudenberger T; Melchior-Becker A; Rübben H; Fischer JW
PLoS One; 2013; 8(9):e75681. PubMed ID: 24069434
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic Acid-Bilirubin Nanoparticles as a Tumor Microenvironment Reactive Oxygen Species-Responsive Nanomedicine for Targeted Cancer Therapy.
Lee S; Lee SA; Shinn J; Lee Y
Int J Nanomedicine; 2024; 19():4893-4906. PubMed ID: 38828202
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid nanogels with enzyme-sensitive cross-linking group for drug delivery.
Yang C; Wang X; Yao X; Zhang Y; Wu W; Jiang X
J Control Release; 2015 May; 205():206-17. PubMed ID: 25665867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
